{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:09:12Z","timestamp":1782364152262,"version":"3.54.5"},"reference-count":284,"publisher":"National Institute for Health and Care Research","issue":"100","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["10\/97\/01"],"award-info":[{"award-number":["10\/97\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title><jats:p>Various lipid measurements in monitoring\/screening programmes can be used, alone or in cardiovascular risk scores, to guide treatment for prevention of cardiovascular disease (CVD). Because some changes in lipids are due to variability rather than true change, the value of lipid-monitoring strategies needs evaluation.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-2\"><jats:title>Objective<\/jats:title><jats:p>To determine clinical value and cost-effectiveness of different monitoring intervals and different lipid measures for primary and secondary prevention of CVD.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-3\"><jats:title>Data sources<\/jats:title><jats:p>We searched databases and clinical trials registers from 2007 (including the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, the Clinical Trials Register, the Current Controlled Trials register, and the Cumulative Index to Nursing and Allied Health Literature) to update and extend previous systematic reviews. Patient-level data from the Clinical Practice Research Datalink and St Luke\u2019s Hospital, Japan, were used in statistical modelling. Utilities and health-care costs were drawn from the literature.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-4\"><jats:title>Methods<\/jats:title><jats:p>In two meta-analyses, we used prospective studies to examine associations of lipids with CVD and mortality, and randomised controlled trials to estimate lipid-lowering effects of atorvastatin doses. Patient-level data were used to estimate progression and variability of lipid measurements over time, and hence to model lipid-monitoring strategies. Results are expressed as rates of true-\/false-positive and true-\/false-negative tests for high lipid or high CVD risk. We estimated incremental costs per quality-adjusted life-year.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-5\"><jats:title>Results<\/jats:title><jats:p>A total of 115 publications reported strength of association between different lipid measures and CVD events in 138 data sets. The summary adjusted hazard ratio per standard deviation of total cholesterol (TC) to high-density lipoprotein (HDL) cholesterol ratio was 1.25 (95% confidence interval 1.15 to 1.35) for CVD in a primary prevention population but heterogeneity was high (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200998%); similar results were observed for non-HDL cholesterol, apolipoprotein B and other ratio measures. Associations were smaller for other single lipid measures. Across 10 trials, low-dose atorvastatin (10 and 20\u2009mg) effects ranged from a TC reduction of 0.92\u2009mmol\/l to 2.07\u2009mmol\/l, and low-density lipoprotein reduction of between 0.88\u2009mmol\/l and 1.86\u2009mmol\/l. Effects of 40\u2009mg and 80\u2009mg were reported by one trial each. For primary prevention, over a 3-year period, we estimate annual monitoring would unnecessarily treat 9 per 1000 more men (28 vs. 19 per 1000) and 5 per 1000 more women (17 vs. 12 per 1000) than monitoring every 3 years. However, annual monitoring would also undertreat 9 per 1000 fewer men (7 vs. 16 per 1000) and 4 per 1000 fewer women (7 vs. 11 per 1000) than monitoring at 3-year intervals. For secondary prevention, over a 3-year period, annual monitoring would increase unnecessary treatment changes by 66 per 1000 men and 31 per 1000 women, and decrease undertreatment by 29 per 1000 men and 28 per 1000 men, compared with monitoring every 3 years. In cost-effectiveness, strategies with increased screening\/monitoring dominate. Exploratory analyses found that any unknown harms of statins would need utility decrements as large as 0.08 (men) to 0.11 (women) per statin user to reverse this finding in primary prevention.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-6\"><jats:title>Limitation<\/jats:title><jats:p>Heterogeneity in meta-analyses.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-7\"><jats:title>Conclusions<\/jats:title><jats:p>While acknowledging known and potential unknown harms of statins, we find that more frequent monitoring strategies are cost-effective compared with others. Regular lipid monitoring in those with and without CVD is likely to be beneficial to patients and to the health service. Future research should include trials of the benefits and harms of atorvastatin 40 and 80\u2009mg, large-scale surveillance of statin safety, and investigation of the effect of monitoring on medication adherence.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-8\"><jats:title>Study registration<\/jats:title><jats:p>This study is registered as PROSPERO CRD42013003727.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-9\"><jats:title>Funding<\/jats:title><jats:p>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta191000","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T11:27:50Z","timestamp":1450783670000},"page":"1-402","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling"],"prefix":"10.3310","volume":"19","author":[{"given":"Rafael","family":"Perera","sequence":"first","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"McFadden","sequence":"additional","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"McLellan","sequence":"additional","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Lung","sequence":"additional","affiliation":[{"name":"Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Clarke","sequence":"additional","affiliation":[{"name":"Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fanshawe","sequence":"additional","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dalton","sequence":"additional","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Farmer","sequence":"additional","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Glasziou","sequence":"additional","affiliation":[{"name":"Bond University, Gold Coast, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"St Luke\u2019s International University Center for Clinical Epidemiology, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stevens","sequence":"additional","affiliation":[{"name":"Patient and public involvement representative, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Les","family":"Irwig","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hirst","sequence":"additional","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stevens","sequence":"additional","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Leslie","sequence":"additional","affiliation":[{"name":"St Luke\u2019s International University Center for Clinical Epidemiology, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Ohde","sequence":"additional","affiliation":[{"name":"St Luke\u2019s International University Center for Clinical Epidemiology, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Deshpande","sequence":"additional","affiliation":[{"name":"St Luke\u2019s International University Center for Clinical Epidemiology, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Urayama","sequence":"additional","affiliation":[{"name":"St Luke\u2019s International University Center for Clinical Epidemiology, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shine","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stevens","sequence":"additional","affiliation":[{"name":"National Institute for Health Research School for Primary Care Research, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2015,12]]},"reference":[{"key":"key20151218094309314_ref1-bib1","volume-title":"Coronary Heart Disease Statistics","author":"Townsend","year":"2012"},{"key":"key20151218094309314_ref1-bib2","volume-title":"Clinical Guidelines and Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease","author":"Cooper","year":"2010"},{"key":"key20151218094309314_ref1-bib3","volume-title":"Cardiovascular Disease \u2013 NHS Choices","author":"NHS Choices","year":"2014"},{"key":"key20151218094309314_ref1-bib4","volume-title":"PH25 Prevention of Cardiovascular Disease: Guidance","author":"National Institute for Health and Care Excellence (NICE)","year":"2010"},{"key":"key20151218094309314_ref1-bib5","volume-title":"Putting Prevention First \u2013 Vascular Checks: Risk Assessment and Management","author":"Department of Health (DH)","year":"2008"},{"key":"key20151218094309314_ref1-bib6","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"key20151218094309314_ref1-bib7","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/S0195-668X(03)00471-8","article-title":"Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias","volume":"24","author":"Emberson","year":"2003","journal-title":"Eur Heart J"},{"key":"key20151218094309314_ref1-bib8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/01.CIR.0000118498.35499.B2","article-title":"Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000","volume":"109","author":"Unal","year":"2004","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib9","volume-title":"Risk Estimation and the Prevention of Cardiovascular Disease (Guideline 97)","author":"Scottish Intercollegiate Guidelines Network (SIGN)","year":"2007"},{"key":"key20151218094309314_ref1-bib10","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1136\/hrt.2005.079988","article-title":"JBS 2: Joint British Societies\u2019 guidelines on prevention of cardiovascular disease in clinical practice","volume":"91","author":"British Cardiac Society","year":"2005","journal-title":"Heart"},{"key":"key20151218094309314_ref1-bib11","doi-asserted-by":"crossref","DOI":"10.1002\/9780470696323","volume-title":"Evidence-Based Medical Monitoring: From Principles to Practice","author":"Glasziou","year":"2008"},{"key":"key20151218094309314_ref1-bib12","doi-asserted-by":"publisher","first-page":"d1289","DOI":"10.1136\/bmj.d1289","article-title":"Adequacy of reporting monitoring regimens of risk factors for cardiovascular disease in clinical guidelines: systematic review","volume":"342","author":"Moschetti","year":"2011","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib13","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib14","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1161\/01.CIR.0000146339.57154.9B","article-title":"Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines","volume":"110","author":"Shai","year":"2004","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib15","volume-title":"Drug Class Review: HMG-CoA Reductase Inhibitors (Statins)","author":"Smith"},{"key":"key20151218094309314_ref1-bib16","first-page":"1","volume-title":"NICE Technical Appraisal 94. Statins for the Prevention of Cardiovascular Events","author":"National Institute for Health and Care Excellence (NICE)","year":"2006"},{"key":"key20151218094309314_ref1-bib17","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3399\/bjgp11X556245","article-title":"The rise of cholesterol testing: how much is unnecessary","volume":"61","author":"Doll","year":"2011","journal-title":"Br J Gen Pract"},{"key":"key20151218094309314_ref1-bib18","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib20","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0002-9149(97)00904-1","article-title":"Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S)","volume":"81","author":"Pedersen","year":"1998","journal-title":"Am J Cardiol"},{"issue":"1","key":"key20151218094309314_ref1-bib22","article-title":"Cholesterol and coronary heart disease: screening and treatment","volume":"4","author":"NHS Centre for Reviews and Dissemination University of York","year":"1998","journal-title":"Eff Heal Care"},{"key":"key20151218094309314_ref1-bib23","volume-title":"National Service Framework for Coronary Heart Disease","author":"Department of Health (DH)","year":"2000"},{"key":"key20151218094309314_ref1-bib24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib25","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Heart Protection Study Collaborative Group","year":"2003","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib26","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0140-6736(04)16284-3","article-title":"OTC statins: a bad decision for public health","volume":"363","author":"The Lancet, Editorial","year":"2004","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib27","doi-asserted-by":"publisher","first-page":"d4350","DOI":"10.1136\/bmj.d4350","article-title":"Statin prescriptions in UK now total a million each week","volume":"343","author":"Trusler","year":"2011","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib28","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/bmj.330.7492.644","article-title":"Monitoring in chronic disease: a rational approach","volume":"330","author":"Glasziou","year":"2005","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib29","doi-asserted-by":"crossref","DOI":"10.1002\/9780470750568","volume-title":"Clinical Thinking: Evidence, Communication and Decision-Making","author":"Del Mar","year":"2006"},{"key":"key20151218094309314_ref1-bib30","doi-asserted-by":"publisher","first-page":"656","DOI":"10.7326\/0003-4819-148-9-200805060-00005","article-title":"Monitoring cholesterol levels: measurement error or true change?","volume":"148","author":"Glasziou","year":"2008","journal-title":"Ann Intern Med"},{"key":"key20151218094309314_ref1-bib31","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/hrt.2009.172619","article-title":"Lipid re-screening: what is the best measure and interval?","volume":"96","author":"Takahashi","year":"2010","journal-title":"Heart"},{"key":"key20151218094309314_ref1-bib32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/0962280209359886","article-title":"Statistical models for the control phase of clinical monitoring","volume":"19","author":"Stevens","year":"2010","journal-title":"Stat Methods Med Res"},{"key":"key20151218094309314_ref1-bib33","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0002-9149(99)80133-7","article-title":"Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: a randomized trial in patients with previous acute myocardial infarction and\/or unstable angina pectoris","volume":"76","author":"The LIPID Study Group","year":"1995","journal-title":"Am J Cardiol"},{"key":"key20151218094309314_ref1-bib34","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib35","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1161\/01.CIR.83.6.2154","article-title":"Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health","volume":"83","author":"Carleton","year":"1991","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib36","first-page":"37","article-title":"A scoring system to identify men at high risk of a heart attack","volume":"19","author":"Shaper","year":"1987","journal-title":"Health Trends"},{"key":"key20151218094309314_ref1-bib37","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(02)09299-1","article-title":"Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs","volume":"359","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib38","doi-asserted-by":"publisher","first-page":"641","DOI":"10.7326\/0003-4819-121-9-199411010-00002","article-title":"Cholesterol and coronary heart disease: predicting risks by levels and ratios","volume":"121","author":"Kinosian","year":"1994","journal-title":"Ann Intern Med"},{"key":"key20151218094309314_ref1-bib39","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jama.294.3.326","article-title":"Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women","volume":"294","author":"Ridker","year":"2005","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib40","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/jama.298.7.776","article-title":"Clinical utility of different lipid measures for prediction of coronary heart disease in men and women","volume":"298","author":"Ingelsson","year":"2007","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib41","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Prospective Studies Collaboration (PSC)","year":"2007","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib42","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.1995.03530100041032","article-title":"Identifying adults at increased risk of coronary disease","volume":"274","author":"Grover","year":"1995","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib43","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"key20151218094309314_ref1-bib44","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib45","first-page":"23","article-title":"Compliance with statins in primary","volume":"272","author":"Howell","year":"2004","journal-title":"Pharm J"},{"key":"key20151218094309314_ref1-bib46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib47","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/bmj.38398.408032.8F","article-title":"Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials","volume":"330","author":"Wei","year":"2005","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib48","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/hrt.2004.053645","article-title":"Over 20,000 avoidable coronary deaths in England and Wales in 2000: the failure to give effective treatments to many eligible patients","volume":"92","author":"Capewell","year":"2006","journal-title":"Heart"},{"key":"key20151218094309314_ref1-bib49","volume-title":"Screening for Lipid Disorders in Adults: U.S. Preventive Services Task Force Recommendation Statement","author":"United States Preventive Services Task Force"},{"key":"key20151218094309314_ref1-bib50","volume-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report)","author":"Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults","year":"2002"},{"key":"key20151218094309314_ref1-bib51","volume-title":"Reducing Risk in Heart Disease: an Expert Guide to Clinical Practice for Secondary Prevention of Coronary Heart Disease","author":"Heart Foundation and Cardiac Society of Australia and New Zealand","year":"2012"},{"key":"key20151218094309314_ref1-bib52","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","article-title":"Cardiovascular disease risk profiles","volume":"121","author":"Anderson","year":"1991","journal-title":"Am Heart J"},{"key":"key20151218094309314_ref1-bib54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/hrt.2006.108167","article-title":"Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC)","volume":"93","author":"Woodward","year":"2007","journal-title":"Heart"},{"key":"key20151218094309314_ref1-bib55","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(02)11890-3","article-title":"Fire-and-forget in prevention of coronary heart disease","volume":"360","author":"Karpe","year":"2002","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib56","volume-title":"NICE Clinical Guideline 181. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease","author":"National Institute for Health and Care Excellence (NICE)","year":"2014"},{"key":"key20151218094309314_ref1-bib57","volume-title":"Simvastatin: Increased Risk of Myopathy at High Dose (80\u2009mg)","author":"Medicines and Healthcare products Regulatory Agency (MHRA)"},{"key":"key20151218094309314_ref1-bib58","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80\u2009mg versus 20\u2009mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group","year":"2010","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib59","volume-title":"Oxfordshire CCG Lipid Management Guidance Updated April 2013","author":"Tully","year":"2013"},{"key":"key20151218094309314_ref1-bib60","volume-title":"Lipid Management Guidelines \u2013 2013","author":"South West Yorkshire Area Prescribing Committee (SWYAPC)","year":"2013"},{"key":"key20151218094309314_ref1-bib61","volume-title":"Summary of the Development Clinical Guideline on Lipid Modification (Update)","author":"National Institute for Health and Care Excellence (NICE)","year":"2014"},{"key":"key20151218094309314_ref1-bib62","volume-title":"Lipid Modification (Update): Guideline Consultation","author":"National Institute for Health and Care Excellence (NICE)","year":"2014"},{"key":"key20151218094309314_ref1-bib63","volume-title":"QOF Business Rules v27.1. Data and Business Rules \u2013 Secondary Prevention of Coronary Heart Disease (CHD) Indicator Set","author":"Department of Health (DH)","year":"2013"},{"key":"key20151218094309314_ref1-bib64","volume-title":"2014\/2015 General Medical Services (GMS) Contract. Quality and Outcomes Framework (QOF). Guidance for GMS Contract 2014\/2015","author":"NHS Employers"},{"key":"key20151218094309314_ref1-bib65","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/jama.1991.03470120080037","article-title":"Estimating an individual\u2019s true cholesterol level and response to intervention","volume":"266","author":"Irwig","year":"1991","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib66","volume-title":"CTT (Cholesterol Treatment Trialists\u2019 Collaboration) \u2013 CTSU","author":"CTSV"},{"key":"key20151218094309314_ref1-bib67","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.annepidem.2005.01.005","article-title":"A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region","volume":"15","author":"Barzi","year":"2005","journal-title":"Ann Epidemiol"},{"key":"key20151218094309314_ref1-bib68","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2796.2006.01644.x","article-title":"Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B\/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies","volume":"259","author":"Thompson","year":"2006","journal-title":"J Intern Med"},{"key":"key20151218094309314_ref1-bib69","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib70","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1001\/jama.2012.6571","article-title":"Lipid-related markers and cardiovascular disease prediction","volume":"307","author":"Emerging Risk Factors Collaboration","year":"2012","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib71","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circulation Cardiovasc Qual Outcomes"},{"key":"key20151218094309314_ref1-bib72","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib73","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.amjcard.2012.07.007","article-title":"Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials","volume":"110","author":"Robinson","year":"2012","journal-title":"Am J Cardiol"},{"key":"key20151218094309314_ref1-bib74","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/bmj.38336.804167.47","article-title":"Optimal search strategies for retrieving systematic reviews from MEDLINE: analytical survey","volume":"330","author":"Montori","year":"2005","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jclinepi.2006.04.001","article-title":"EMBASE search strategies achieved high sensitivity and specificity for retrieving methodologically sound systematic reviews","volume":"60","author":"Wilczynski","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"key20151218094309314_ref1-bib76","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10654-007-9165-7","article-title":"The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases","volume":"22","author":"Emerging Risk Factors Collaboration","year":"2007","journal-title":"Eur J Epidemiol"},{"key":"key20151218094309314_ref1-bib77","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"key20151218094309314_ref1-bib78","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s001340101076","article-title":"Systematic review of prediction of poor outcome in anoxic-ischaemic coma with biochemical markers of brain damage","volume":"27","author":"Zandbergen","year":"2001","journal-title":"Intensive Care Med"},{"key":"key20151218094309314_ref1-bib79","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1472-6947-6-38","article-title":"Systematic review of prognostic models in traumatic brain injury","volume":"6","author":"Perel","year":"2006","journal-title":"BMC Med Inf Decis Mak"},{"key":"key20151218094309314_ref1-bib80","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"key20151218094309314_ref1-bib81","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/sj.bjc.6600886","article-title":"Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future","volume":"88","author":"Riley","year":"2003","journal-title":"Br J Cancer"},{"key":"key20151218094309314_ref1-bib82","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/oxfordjournals.aje.a116237","article-title":"Methods for trend estimation from summarized dose-response data, with applications to meta-analysis","volume":"135","author":"Greenland","year":"1992","journal-title":"Am J Epidemiol"},{"key":"key20151218094309314_ref1-bib83","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1536867X0600600103","article-title":"Generalized least squares for trend estimation of summarized dose\u2013response data","volume":"6","author":"Orsini","year":"2006","journal-title":"Stata J"},{"key":"key20151218094309314_ref1-bib84","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/jnci\/dji184","article-title":"Selective reporting biases in cancer prognostic factor studies","volume":"97","author":"Kyzas","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key20151218094309314_ref1-bib85","volume-title":"HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events)","author":"HPS2-THRIVE"},{"key":"key20151218094309314_ref1-bib86","first-page":"203","article-title":"POlish-Norwegian Study (PONS): research on chronic non-communicable diseases in European high risk countries \u2013 study design","volume":"18","author":"Zatonski","year":"2011","journal-title":"Ann Agri Environ Med"},{"key":"key20151218094309314_ref1-bib87","volume-title":"Prevention of Cardiovascular Disease in Middle-Aged and Elderly Iranians using a Single PolyPill (PolyIran)","author":"Tehran University of Medical Sciences"},{"key":"key20151218094309314_ref1-bib88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1476-511X-9-6","article-title":"Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8.6 years follow-up of a population based cohort study","volume":"9","author":"Tohidi","year":"2010","journal-title":"Lipids Health Dis"},{"key":"key20151218094309314_ref1-bib89","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/aje\/152.5.420","article-title":"Plasma fibrinogen and coronary heart disease in urban Japanese","volume":"152","author":"Sato","year":"2000","journal-title":"Am J Epidemiol"},{"key":"key20151218094309314_ref1-bib90","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2796.2008.01925.x","article-title":"Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short vs. longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS)","volume":"264","author":"Holme","year":"2008","journal-title":"J Intern Med"},{"key":"key20151218094309314_ref1-bib91","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1136\/bmj.311.7008.779","article-title":"Total cholesterol concentration and mortality at a relatively young age: do men and women differ?","volume":"311","author":"Verschuren","year":"1995","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib92","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib93","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1445-5994.1996.tb02905.x","article-title":"Predictors of mortality in the prospective Dubbo study of Australian elderly","volume":"26","author":"Simons","year":"1996","journal-title":"Aust N Z J Med"},{"key":"key20151218094309314_ref1-bib94","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/0895-4356(94)90110-4","article-title":"Serum total cholesterol and mortality in a Japanese population","volume":"47","author":"Iso","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"key20151218094309314_ref1-bib95","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/eurheartj\/ehi003","article-title":"Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA\/KORA Augsburg cohort study","volume":"26","author":"Meisinger","year":"2005","journal-title":"Eur Heart J"},{"key":"key20151218094309314_ref1-bib96","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1538-7836.2007.02330.x","article-title":"Long-term effects of hemostatic variables on fatal coronary heart disease: 30-year results from the first prospective Northwick Park Heart Study (NPHS-I)","volume":"5","author":"De Stavola","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key20151218094309314_ref1-bib97","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00043798-200204000-00001","article-title":"Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study","volume":"9","author":"Jonsd\u00f3ttir","year":"2002","journal-title":"Eur J Cardiovasc Risk"},{"key":"key20151218094309314_ref1-bib98","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1046\/j.1365-2796.1999.00525.x","article-title":"Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam study","volume":"246","author":"Houterman","year":"1999","journal-title":"J Intern Med"},{"key":"key20151218094309314_ref1-bib99","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199307083290201","article-title":"Mortality rates and risk factors for coronary disease in black as compared with white men and women","volume":"329","author":"Keil","year":"1993","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1365-2362.2010.02357.x","article-title":"Lipid assessment, metabolic syndrome and coronary heart disease risk","volume":"40","author":"European Prospective Investigation into Cancer and Nutrition-Norfolk study","year":"2010","journal-title":"Eur J Clin Invest"},{"key":"key20151218094309314_ref1-bib101","first-page":"101","volume-title":"Progress in Cardiology","author":"Garcia-Palmieri","year":"1986"},{"key":"key20151218094309314_ref1-bib102","first-page":"536","article-title":"Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the Usual-Care Group of the Multiple Risk Factor Intervention Trial","volume":"57","author":"Watkins","year":"1966","journal-title":"Am J Cardiol"},{"key":"key20151218094309314_ref1-bib103","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/jech.52.10.638","article-title":"Comparative total mortality in 25 years in Italian and Greek middle aged rural men","volume":"52","author":"Dontas","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"key20151218094309314_ref1-bib104","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/oxfordjournals.aje.a008724","article-title":"Total and high density lipoprotein cholesterol as risk factors for coronary heart disease in elderly men during 5 years of follow-up. The Zutphen Elderly Study","volume":"143","author":"Weijenberg","year":"1996","journal-title":"Am J Epidemiol"},{"key":"key20151218094309314_ref1-bib105","first-page":"11","article-title":"Coronary heart disease in 25 years. The experience in the three Serbian cohorts of the Seven Countries Study","volume":"1","author":"Nedeljkovic","year":"1993","journal-title":"Acta Cardiol"},{"key":"key20151218094309314_ref1-bib106","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib107","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/j.1600-6143.2004.00445.x","article-title":"Fluvastatin prevents cardiac death and myocardial infraction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study","volume":"4","author":"Jardine","year":"2004","journal-title":"Am J Transplant"},{"key":"key20151218094309314_ref1-bib108","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ypmed.2009.07.019","article-title":"Central obesity and cigarette smoking are key determinants of CVD deaths in Australia: a public health perspective","volume":"49","author":"Dhaliwal","year":"2009","journal-title":"Prev Med"},{"key":"key20151218094309314_ref1-bib109","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","article-title":"Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial \u2013 Lipid-Lowering Arm (ASCOT-LLA)","volume":"28","author":"Sever","year":"2005","journal-title":"Diabetes Care"},{"key":"key20151218094309314_ref1-bib110","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib111","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/bmj.298.6679.998","article-title":"Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease","volume":"298","author":"Pocock","year":"1989","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib112","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcome: prospective results from the Bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20151218094309314_ref1-bib113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(94)90814-1","article-title":"Apolipoproteins and ischaemic heart disease: implications for screening","volume":"343","author":"Wald","year":"1994","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib114","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1046\/j.1365-2362.2000.00725.x","article-title":"Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study","volume":"30","author":"Sweetnam","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"key20151218094309314_ref1-bib115","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib116","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00125-006-0195-6","article-title":"Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study","volume":"49","author":"Bruno","year":"2006","journal-title":"Diabetologia"},{"key":"key20151218094309314_ref1-bib117","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/1471-2458-7-290","article-title":"All-cause mortality and risk factors in a cohort of retired military male veterans, Xi\u2019an, China: an 18-year follow up study","volume":"7","author":"Sai","year":"2007","journal-title":"BMC Public Health"},{"key":"key20151218094309314_ref1-bib118","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1111\/j.1532-5415.2004.52455.x","article-title":"The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study","volume":"52","author":"Psaty","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"key20151218094309314_ref1-bib119","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib120","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.2337\/dc08-1013","article-title":"Recurrence of cardiovascular events in patients with type 2 diabetes","volume":"31","author":"Giorda","year":"2008","journal-title":"Diabetes Care"},{"key":"key20151218094309314_ref1-bib121","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1007\/s00125-010-1806-9","article-title":"Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes","volume":"53","author":"Taskinen","year":"2010","journal-title":"Diabetologia"},{"key":"key20151218094309314_ref1-bib122","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1161\/hq0202.104078","article-title":"Hemostatic factors as predictors of coronary events and total mortality: The FINRISK \u201892 Hemostasis Study","volume":"22","author":"Salomaa","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20151218094309314_ref1-bib123","first-page":"810","article-title":"Results of the low-dose (20\u2009mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?","volume":"1","author":"GISSI Prevenzione Investigators","year":"2000","journal-title":"Ital Heart J"},{"key":"key20151218094309314_ref1-bib124","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0021-9150(97)00071-3","article-title":"Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case\u2013control study","volume":"132","author":"Klausen","year":"1997","journal-title":"Atherosclerosis"},{"key":"key20151218094309314_ref1-bib125","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ypmed.2004.10.020","article-title":"The role of risk factor time trends in the steep decline of CHD mortality between two Israeli cohort studies","volume":"41","author":"Gerber","year":"2005","journal-title":"Prev Med"},{"key":"key20151218094309314_ref1-bib126","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0021-9150(96)06030-3","article-title":"Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men","volume":"129","author":"Cremer","year":"1997","journal-title":"Atherosclerosis"},{"key":"key20151218094309314_ref1-bib127","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3748\/wjg.v13.i10.1579","article-title":"Non-alcoholic fatty liver disease is a novel predictor of CVD","volume":"13","author":"Hamaguchi","year":"2007","journal-title":"World J Gastroenterol"},{"key":"key20151218094309314_ref1-bib128","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(01)05553-2","article-title":"Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study","volume":"358","author":"Schatz","year":"2001","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib129","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00125-003-1141-5","article-title":"A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for CVD in subjects with abnormal glucose metabolism: The Hoorn Study","volume":"46","author":"Bos","year":"2003","journal-title":"Diabetologia"},{"key":"key20151218094309314_ref1-bib130","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.2337\/diacare.27.8.1991","article-title":"Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes","volume":"27","author":"Jiang","year":"2004","journal-title":"Diabetes Care"},{"key":"key20151218094309314_ref1-bib131","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/j.1532-5415.2009.02438.x","article-title":"Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults","volume":"57","author":"Semba","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"key20151218094309314_ref1-bib132","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000175862","article-title":"Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees","volume":"8","author":"Goldbourt","year":"1993","journal-title":"Cardiology"},{"key":"key20151218094309314_ref1-bib133","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5551\/jat.5215","article-title":"Serum low-density lipoprotein to high density lipoprotein ratio as a predictor of future acute myocardial infarction among men in a 2.7-year cohort study of a Japanese northern rural population","volume":"18","author":"Yokokawa","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"key20151218094309314_ref1-bib134","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2011.12.012","article-title":"Non-high-density lipoprotein cholesterol is a practical predictor of long-term cardiac death after coronary artery bypass grafting","volume":"221","author":"Fukushima","year":"2012","journal-title":"Atherosclerosis"},{"key":"key20151218094309314_ref1-bib135","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/archinte.160.8.1160","article-title":"Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men","volume":"160","author":"Lakka","year":"2000","journal-title":"Arch Intern Med"},{"key":"key20151218094309314_ref1-bib136","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.archger.2007.02.001","article-title":"Clinical and laboratory predictors of all-cause mortality in older population","volume":"45","author":"Lan","year":"2007","journal-title":"Arch Gerontol Geriatr"},{"key":"key20151218094309314_ref1-bib137","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/sj.jhh.1002203","article-title":"Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study","volume":"21","author":"De Simone","year":"2007","journal-title":"J Hum Hypertens"},{"key":"key20151218094309314_ref1-bib138","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/hc1002.105136","article-title":"Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?","volume":"105","author":"Simes","year":"2002","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib139","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1532-5415.2011.03851.x","article-title":"Low high-density lipoprotein 3 reduces the odds of men surviving to age 85 during 53-year follow-up","volume":"60","author":"Williams","year":"2012","journal-title":"JAGS"},{"key":"key20151218094309314_ref1-bib140","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.1995.03530100041032","article-title":"Identifying adults at increased risk of coronary disease","volume":"274","author":"Grover","year":"1995","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib141","doi-asserted-by":"publisher","first-page":"176","DOI":"10.5551\/jat.9183","article-title":"Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia","volume":"19","author":"Mizuno","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"key20151218094309314_ref1-bib142","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jacl.2010.12.001","article-title":"Comparative prognostic utility of conventional and novel lipid parameters for CVD risk prediction: do novel lipid parameters offer an advantage?","volume":"5","author":"Manickam","year":"2011","journal-title":"J Clin Lipidol"},{"key":"key20151218094309314_ref1-bib143","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jclinepi.2006.04.010","article-title":"In a population-based cohort of diabetes patients, men and women had similar risks for all-cause mortality","volume":"60","author":"Shalev","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"key20151218094309314_ref1-bib144","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/eurheartj\/ehn347","article-title":"Concentration of apolipoprotein B is comparable with the apolipoprotein B\/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population","volume":"30","author":"Sierra-Johnson","year":"2009","journal-title":"Eur Heart J"},{"key":"key20151218094309314_ref1-bib145","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2006.01.024","article-title":"The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort","volume":"190","author":"Okamura","year":"2007","journal-title":"Atherosclerosis"},{"key":"key20151218094309314_ref1-bib146","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1161\/01.CIR.102.23.2816","article-title":"Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease","volume":"102","author":"Cooper","year":"2000","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib147","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1161\/01.CIR.0000146339.57154.9B","article-title":"Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines","volume":"110","author":"Shai","year":"2004","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib148","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/bjs.5626","article-title":"Cholesterol and serum albumin as risk factors for death in patients undergoing general surgery","volume":"94","author":"Palma","year":"2007","journal-title":"Br J Surg"},{"key":"key20151218094309314_ref1-bib149","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/oxfordjournals.aje.a114435","article-title":"Is the level of serum triglyceride a significant predictor of coronary death in \u2018normocholesterolemic\u2019 subjects?","volume":"124","author":"Cambien","year":"1986","journal-title":"Am J Epidemiol"},{"key":"key20151218094309314_ref1-bib150","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1056\/NEJM199108083250601","article-title":"A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infraction","volume":"325","author":"Stampfer","year":"1991","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib151","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/art.23121","article-title":"Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease","volume":"58","author":"Preventive Cardiology Information System Database Cohort Study","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key20151218094309314_ref1-bib152","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2796.2010.02323.x","article-title":"Apolipoprotein B\/A-I and total cholesterol\/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein","volume":"269","author":"Kappelle","year":"2011","journal-title":"J Intern Med"},{"key":"key20151218094309314_ref1-bib153","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/hc0302.102575","article-title":"Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular M\u00fcnster (PROCAM) Study","volume":"105","author":"Assmann","year":"2002","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib154","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/01.hjr.0000221866.27039.4b","article-title":"Favorable cardiovascular risk profile and 10-year coronary heart disease incidence in women and men: results from the Progetto Cuore","volume":"13","author":"Palmieri","year":"2006","journal-title":"Eur J Cardiovasc Prevent Rehabil"},{"key":"key20151218094309314_ref1-bib155","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib156","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/01.ATV.0000154144.73236.f4","article-title":"Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Qu\u00e9bec Cardiovascular Study","volume":"25","author":"St-Pierre","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20151218094309314_ref1-bib157","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0002-9149(03)00319-9","article-title":"Sex and time differences in the associations of non-high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (The Rancho Bernardo Study)","volume":"91","author":"Rancho Bernardo Study","year":"2003","journal-title":"Am J Cardiol"},{"key":"key20151218094309314_ref1-bib158","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/174182679400100312","article-title":"The prediction of coronary heart disease mortality as a function of major risk factors in over 30,000 men in the Italian RIFLE pooling project. A comparison with the MRFIT primary screening","volume":"1","author":"Menotti","year":"1994","journal-title":"J Cardiovasc Risk"},{"key":"key20151218094309314_ref1-bib159","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1161\/01.CIR.94.10.2381","article-title":"Serum lipids and incidence of coronary heart disease","volume":"94","author":"Frost","year":"1996","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib160","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2337\/diacare.26.1.16","article-title":"Non-HDL cholesterol as a predictor of CVD in type 2 diabetes","volume":"26","author":"Lu","year":"2003","journal-title":"Diabetes Care"},{"key":"key20151218094309314_ref1-bib161","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jacl.2012.02.011","article-title":"Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and non-high-density lipoprotein cholesterol in men","volume":"6","author":"Abdel-Maksoud","year":"2012","journal-title":"J Clin Lipidol"},{"key":"key20151218094309314_ref1-bib162","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1185\/030079906X167660","article-title":"Risk of cardiovascular events in patients at optimal values for combined lipid parameters","volume":"23","author":"Stanek","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"key20151218094309314_ref1-bib163","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1136\/heartjnl-2012-301852","article-title":"Elevated Apo B serum levels strongly predict early cardiovascular events","volume":"98","author":"Gigante","year":"2012","journal-title":"Heart"},{"key":"key20151218094309314_ref1-bib164","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2337\/dc11-0209","article-title":"Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes","volume":"34","author":"Eliasson","year":"2011","journal-title":"Diabetes Care"},{"key":"key20151218094309314_ref1-bib165","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/01.CIR.99.19.2517","article-title":"Thrombogenic factors and recurrent coronary events","volume":"99","author":"Moss","year":"1999","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib166","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1475-2840-9-77","article-title":"Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study","volume":"9","author":"Ting","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"key20151218094309314_ref1-bib167","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ahj.2011.07.016","article-title":"Predictors of fatal and non-fatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)","volume":"162","author":"McMurray","year":"2011","journal-title":"Am Heart J"},{"key":"key20151218094309314_ref1-bib168","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/BF03327441","article-title":"Serum lipids and their association with mortality in the elderly: a prospective cohort study","volume":"21","author":"Upmeier","year":"2009","journal-title":"Aging Clin Exp Res"},{"key":"key20151218094309314_ref1-bib169","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ahj.2004.03.021","article-title":"Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B\/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM)","volume":"148","author":"Dunder","year":"2004","journal-title":"Am Heart J"},{"key":"key20151218094309314_ref1-bib170","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Bloomfield","year":"1999","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib171","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.1992.03480010078028","article-title":"Plasma cholesterol concentration and mortality","volume":"267","author":"Davey Smith","year":"1992","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib172","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jama.294.3.326","article-title":"Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for CVD in women","volume":"294","author":"Ridker","year":"2005","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib173","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1161\/01.CIR.102.23.2816","article-title":"Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease","volume":"102","author":"Cooper","year":"2000","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib174","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1253\/circj.66.1087","article-title":"Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia","volume":"66","author":"Primary Prevention Cohort Study of the Japan Lipid Intervention Trial","year":"2002","journal-title":"Circ J"},{"key":"key20151218094309314_ref1-bib175","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1253\/circj.66.1096","article-title":"Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease","volume":"66","author":"Secondary Prevention Cohort Study of the Japan Lipid Intervention Trial","year":"2002","journal-title":"Circ J"},{"key":"key20151218094309314_ref1-bib176","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib177","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5551\/jat.9.99","article-title":"Prognosis of hypercholesterolemic patients taking pravastatin for 5 years: the Chiba lipid intervention program (CLIP) study","volume":"9","author":"Saito","year":"2002","journal-title":"J Atheroscler Thromb"},{"key":"key20151218094309314_ref1-bib178","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib179","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study \u2013 a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib180","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5551\/jat.8326","article-title":"Relationship between coronary artery disease and non-HDL-C and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA lipid intervention study (JELIS)","volume":"19","author":"Sasaki","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"key20151218094309314_ref1-bib181","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive Protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib182","first-page":"789","article-title":"A large-scale survey on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia \u2013 LIVALO effectiveness and safety study extension","volume":"39","author":"Teramoto","year":"2011","journal-title":"Jpn Pharmacol Ther"},{"key":"key20151218094309314_ref1-bib183","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/ATVBAHA.108.181735","article-title":"Prognostic utility of Apo B\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22","volume":"29","author":"Ray","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20151218094309314_ref1-bib184","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators","year":"2006","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib185","doi-asserted-by":"crossref","first-page":"e114519","DOI":"10.1371\/journal.pone.0114519","article-title":"Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers","volume":"9","author":"Arsenault","year":"2014","journal-title":"PLOS ONE"},{"key":"key20151218094309314_ref1-bib186","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2014"},{"key":"key20151218094309314_ref1-bib187","doi-asserted-by":"publisher","first-page":"CD008226","DOI":"10.1002\/14651858.cd008226.pub2","article-title":"Lipid lowering efficacy of atorvastatin","volume":"12","author":"Adams","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key20151218094309314_ref1-bib188","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/2047487313483600","article-title":"Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials","volume":"20","author":"Naci","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"key20151218094309314_ref1-bib189","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"2011"},{"key":"key20151218094309314_ref1-bib190","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1536867X0900900103","article-title":"Multivariate random-effects meta-analysis","volume":"9","author":"White","year":"2009","journal-title":"Stata J"},{"key":"key20151218094309314_ref1-bib191","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"key20151218094309314_ref1-bib192","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial \u2013 Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib193","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib194","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jacc.2004.07.053","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the Alliance Study","volume":"44","author":"Koren","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key20151218094309314_ref1-bib195","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/S0002-9149(97)00174-4","article-title":"Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia","volume":"79","author":"Davidson","year":"1997","journal-title":"Am J Cardiol"},{"key":"key20151218094309314_ref1-bib196","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program Goal versus \u2018usual\u2019 care in secondary coronary heart disease prevention","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"key20151218094309314_ref1-bib197","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"key20151218094309314_ref1-bib198","volume-title":"The History of the NHS","author":"NHS Choices","year":"2010"},{"key":"key20151218094309314_ref1-bib199","volume-title":"NHS Health Check","author":"NHS Choices"},{"key":"key20151218094309314_ref1-bib200","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.jacc.2009.10.009","article-title":"Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?","volume":"54","author":"Matthews","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key20151218094309314_ref1-bib201","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1016\/j.jacc.2009.10.008","article-title":"Menopause, age, and cardiovascular risk: a complex relationship","volume":"54","author":"Bittner","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key20151218094309314_ref1-bib202","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/gme.0b013e31818aefef","article-title":"Is age at menopause increasing across Europe? Results on age at menopause and determinants from two population-based studies","volume":"16","author":"Dratva","year":"2009","journal-title":"Menopause"},{"key":"key20151218094309314_ref1-bib203","volume-title":"Clinical Practice Research Datalink","author":"Clinical Practice Research Datalink (CPRD)"},{"key":"key20151218094309314_ref1-bib204","doi-asserted-by":"publisher","first-page":"b1492","DOI":"10.1136\/bmj.b1492","article-title":"Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial","volume":"338","author":"Keenan","year":"2009","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib205","first-page":"1","article-title":"runmlwin: A Program to Run the MLwiN Multilevel Modeling Software from within Stata","volume":"52","author":"Leckie","year":"2013","journal-title":"J Stat Softw"},{"key":"key20151218094309314_ref1-bib206","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1464-5491.2011.03412.x","article-title":"Establishing an evidence base for frequency of monitoring glycated haemoglobin levels in patients with Type 2 diabetes: projections of effectiveness from a regression model","volume":"29","author":"Oke","year":"2012","journal-title":"Diabet Med"},{"key":"key20151218094309314_ref1-bib207","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.diabres.2012.12.010","article-title":"Monitoring young people with type 1 diabetes for diabetic nephropathy: potential errors of annual ACR testing","volume":"99","author":"Oke","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"key20151218094309314_ref1-bib208","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/sim.5935","article-title":"Multiple imputation for an incomplete covariate that is a ratio","volume":"33","author":"Morris","year":"2014","journal-title":"Stat Med"},{"key":"key20151218094309314_ref1-bib209","volume-title":"Reducing your Blood Cholesterol","author":"British Heart Foundation (BHF)","year":"2011"},{"key":"key20151218094309314_ref1-bib210","volume-title":"High Cholesterol \u2013 Diagnosis","author":"NHS Choices","year":"2013"},{"key":"key20151218094309314_ref1-bib211","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2007.06.034","article-title":"Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors","volume":"154","author":"Bowman","year":"2007","journal-title":"Am Heart J"},{"key":"key20151218094309314_ref1-bib212","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/1467-985X.00164","article-title":"Correcting for regression dilution bias: comparison of methods for a single predictor variable","volume":"163","author":"Frost","year":"2000","journal-title":"J R Stat Soc Ser A"},{"key":"key20151218094309314_ref1-bib213","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1042\/cs1010671","article-title":"The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)","volume":"101","author":"Stevens","year":"2001","journal-title":"Clin Sci"},{"key":"key20151218094309314_ref1-bib214","author":"ClinRisk Subversion Repository"},{"key":"key20151218094309314_ref1-bib215","volume-title":"Creating and Using Stata Plugins","author":"StataCorp"},{"key":"key20151218094309314_ref1-bib216","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacc.2009.07.057","article-title":"Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol\/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women","volume":"55","author":"Arsenault","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key20151218094309314_ref1-bib217","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib218","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2307\/2532247","article-title":"Regression dilution in the proportional hazards model","volume":"49","author":"Hughes","year":"1993","journal-title":"Biometrics"},{"key":"key20151218094309314_ref1-bib219","volume-title":"R: A Language and Environment for Statistical Computing","author":"The R Core Team","year":"2013"},{"key":"key20151218094309314_ref1-bib220","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5","article-title":"What do we mean by validating a prognostic model?","volume":"19","author":"Altman","year":"2000","journal-title":"Stat Med"},{"key":"key20151218094309314_ref1-bib221","doi-asserted-by":"publisher","first-page":"201","DOI":"10.7326\/0003-4819-144-3-200602070-00009","article-title":"Translating clinical research into clinical practice: impact of using prediction rules to make decisions","volume":"144","author":"Reilly","year":"2006","journal-title":"Ann Intern Med"},{"key":"key20151218094309314_ref1-bib222","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(97)04248-7","article-title":"The UK General Practice Research Database","volume":"350","author":"Walley","year":"1997","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib223","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/biomet\/69.2.331","article-title":"Covariate measurement errors and parameter estimation in a failure time regression model","volume":"69","author":"Prentice","year":"1982","journal-title":"Biometrika"},{"key":"key20151218094309314_ref1-bib224","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.2307\/2533667","article-title":"Estimating the parameters in the Cox model when covariate variables are measured with error","volume":"54","author":"Hu","year":"1998","journal-title":"Biometrics"},{"key":"key20151218094309314_ref1-bib225","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","article-title":"A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)","volume":"47","author":"Clarke","year":"2004","journal-title":"Diabetologia"},{"key":"key20151218094309314_ref1-bib226","first-page":"1","volume-title":"NICE Care Guideline 67. Lipid Modification: Full Guideline","author":"National Institute for Health and Care Excellence (NICE)","year":"2010"},{"key":"key20151218094309314_ref1-bib227","volume-title":"United States Life Tables Eliminating Certain Causes of Death, 1999\u20132001","author":"Arias","year":"2013"},{"key":"key20151218094309314_ref1-bib228","volume-title":"Category M Prices \u2013 Quarter 2 July 2013","author":"NHS Business Services Authority","year":"2013"},{"key":"key20151218094309314_ref1-bib229","doi-asserted-by":"publisher","first-page":"d1672","DOI":"10.1136\/bmj.d1672","article-title":"Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis","volume":"342","author":"Greving","year":"2011","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib230","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-144-5-200603070-00007","article-title":"Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost\u2013utility analysis","volume":"144","author":"Pignone","year":"2006","journal-title":"Ann Intern Med"},{"key":"key20151218094309314_ref1-bib231","volume-title":"Interim Life Tables, England and Wales, 2009\u20132011","author":"Office for National Statistics (ONS)","year":"2013"},{"key":"key20151218094309314_ref1-bib232","volume-title":"The Green Book: Appraisal and Evaluation in Central Government","author":"HM Treasury","year":"2011"},{"key":"key20151218094309314_ref1-bib233","volume-title":"Unit Costs of Health and Social Care 2010","author":"Curtis","year":"2010"},{"issue":"14","key":"key20151218094309314_ref1-bib234","doi-asserted-by":"publisher","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"key":"key20151218094309314_ref1-bib235","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1046\/j.1464-5491.2003.00972.x","article-title":"The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65)","volume":"20","author":"Clarke","year":"2003","journal-title":"Diabet Med"},{"key":"key20151218094309314_ref1-bib236","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.2337\/dc11-2478","article-title":"Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD)","volume":"35","author":"Zhang","year":"2012","journal-title":"Diabetes Care"},{"key":"key20151218094309314_ref1-bib237","doi-asserted-by":"publisher","first-page":"CD004816","DOI":"10.1002\/14651858.cd004816.pub5","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"1","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key20151218094309314_ref1-bib238","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/2047487314525531","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice","volume":"21","author":"Finegold","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"key20151218094309314_ref1-bib239","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"key20151218094309314_ref1-bib240","first-page":"339","article-title":"Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 ACC\/AHA Cholesterol Guideline. Ann Intern Med","volume":"160","author":"Stone","year":"2014","journal-title":"Am Coll Phys"},{"key":"key20151218094309314_ref1-bib241","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib242","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib243","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib244","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1161\/CIRCULATIONAHA.111.055269","article-title":"Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis","volume":"124","author":"Hackam","year":"2011","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib245","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1161\/STROKEAHA.112.655894","article-title":"Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials","volume":"43","author":"McKinney","year":"2012","journal-title":"Stroke"},{"key":"key20151218094309314_ref1-bib246","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"key20151218094309314_ref1-bib247","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/archinternmed.2012.2171","article-title":"Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial","volume":"172","author":"Golomb","year":"2012","journal-title":"Arch Intern Med"},{"key":"key20151218094309314_ref1-bib248","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib249","doi-asserted-by":"publisher","first-page":"g3743","DOI":"10.1136\/bmj.g3743","article-title":"Non-cardiovascular effects associated with statins","volume":"349","author":"Desai","year":"2014","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib250","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/HYPERTENSIONAHA.110.153775","article-title":"Hypertension awareness and psychological distress","volume":"56","author":"Hamer","year":"2010","journal-title":"Hypertension"},{"key":"key20151218094309314_ref1-bib251","first-page":"301","article-title":"Impact of a policy allowing for over-the-counter statins","volume":"18","author":"Mainous","year":"2010","journal-title":"Qual Prim Care"},{"key":"key20151218094309314_ref1-bib252","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/S0140-6736(00)03246-3","article-title":"Randomised comparisons of medical tests: sometimes invalid, not always efficient","volume":"356","author":"Bossuyt","year":"2000","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib253","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/jhh.2011.72","article-title":"Blood pressure re-screening for healthy adults: what is the best measure and interval?","volume":"26","author":"Takahashi","year":"2012","journal-title":"J Hum Hypertens"},{"key":"key20151218094309314_ref1-bib254","doi-asserted-by":"publisher","first-page":"e003667","DOI":"10.1136\/bmjopen-2013-003667","article-title":"Changes in the rates of weight and waist circumference gain in Australian adults over time: a longitudinal cohort study","volume":"4","author":"Peeters","year":"2014","journal-title":"BMJ Open"},{"key":"key20151218094309314_ref1-bib255","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/MOL.0000000000000021","article-title":"Low-density lipoprotein cholesterol reduction by inhibition of PCSK9","volume":"24","author":"Stein","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"key20151218094309314_ref1-bib256","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-139-8-200310210-00011","article-title":"Effects of statins on nonlipid serum markers associated with cardiovascular disease","volume":"139","author":"Balk","year":"2003","journal-title":"Ann Intern Med"},{"key":"key20151218094309314_ref1-bib257","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1136\/bmj.282.6279.1847","article-title":"Strategy of prevention: lessons from cardiovascular disease","volume":"282","author":"Rose","year":"1981","journal-title":"Br Med J"},{"key":"key20151218094309314_ref1-bib258","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/0895-4356(91)90151-X","article-title":"Strategies of prevention revisited: effects of imprecise measurement of risk factors on the evaluation of \u2018high-risk\u2019 and \u2018population-based\u2019 approaches to prevention of cardiovascular disease","volume":"44","author":"Strachan","year":"1991","journal-title":"J Clin Epidemiol"},{"key":"key20151218094309314_ref1-bib259","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key20151218094309314_ref1-bib260","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","article-title":"ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness","volume":"106","author":"Taylor","year":"2002","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib261","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet"},{"key":"key20151218094309314_ref1-bib262","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1161\/CIRCULATIONAHA.104.512681","article-title":"Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES)","volume":"112","author":"Raggi","year":"2005","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib263","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0021-9150(96)06052-2","article-title":"Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia","volume":"130","author":"Bertolini","year":"1997","journal-title":"Atherosclerosis"},{"key":"key20151218094309314_ref1-bib264","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0735-1097(98)00300-3","article-title":"Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin","volume":"32","author":"Brown","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"key20151218094309314_ref1-bib265","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1185\/03007991003751496","article-title":"Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease","volume":"26","author":"Colivicchi","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"key20151218094309314_ref1-bib266","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jvs.2009.07.119","article-title":"Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization","volume":"51","author":"Kadoglou","year":"2010","journal-title":"J Vasc Surg"},{"key":"key20151218094309314_ref1-bib267","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib268","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"key20151218094309314_ref1-bib269","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.654756","article-title":"Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)","volume":"115","author":"Deedwania","year":"2007","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib270","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.105.568147","article-title":"Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial","volume":"113","author":"Schmermund","year":"2006","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib271","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jacc.2005.06.088","article-title":"Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure","volume":"47","author":"Sola","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key20151218094309314_ref1-bib272","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1161\/01.CIR.0000160866.90148.76","article-title":"Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study","volume":"111","author":"Stone","year":"2005","journal-title":"Circulation"},{"key":"key20151218094309314_ref1-bib273","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"key20151218094309314_ref1-bib274","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"key":"key20151218094309314_ref1-bib275","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1053\/euhj.2001.2781","article-title":"Underestimation of the importance of blood pressure and cholesterol for coronary heart disease mortality in old age","volume":"23","author":"Clarke","year":"2002","journal-title":"Eur Heart J"},{"key":"key20151218094309314_ref1-bib276","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bmj.308.6925.363","article-title":"Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study","volume":"308","author":"Law","year":"1994","journal-title":"BMJ"},{"key":"key20151218094309314_ref1-bib277","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1093\/eurheartj\/ehp221","article-title":"The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls","volume":"30","author":"Parish","year":"2009","journal-title":"Eur Heart J"},{"key":"key20151218094309314_ref1-bib278","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.ehj.2004.04.011","article-title":"Haemostatic\/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies","volume":"25","author":"Yarnell","year":"2004","journal-title":"Eur Heart J"},{"key":"key20151218094309314_ref1-bib279","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/oxfordjournals.aje.a115963","article-title":"Repeat measurement of case-control data: correcting risk estimates for misclassification owing to regression dilution of lipids in transient ischaemic attacks and minor ischaemic strokes","volume":"133","author":"Qizilbash","year":"1991","journal-title":"Am J Epidemiol"},{"key":"key20151218094309314_ref1-bib280","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0021-9150(82)90227-1","article-title":"Intra-individual variation of serum cholesterol, triglycerides and high density lipoprotein cholesterol in normal humans","volume":"45","author":"Demacker","year":"1982","journal-title":"Atherosclerosis"},{"key":"key20151218094309314_ref1-bib281","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0009-9120(99)00030-2","article-title":"Monthly intra-individual variation in lipids over a 1-year period in 22 normal subjects","volume":"32","author":"Nazir","year":"1999","journal-title":"Clin Biochem"},{"key":"key20151218094309314_ref1-bib282","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/clinchem\/39.6.1012","article-title":"Biological variability in concentrations of serum lipids: sources of variation among results from published studies and composite predicted values","volume":"39","author":"Smith","year":"1993","journal-title":"Clin Chem"},{"key":"key20151218094309314_ref1-bib283","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/clinchem\/38.1.56","article-title":"Biological variation data applied to the selection of serum lipid ratios used as risk markers of coronary heart disease","volume":"38","author":"Ortol\u00e1","year":"1992","journal-title":"Clin Chem"},{"key":"key20151218094309314_ref1-bib284","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2005.03.032","article-title":"Less than 50% of variation in HDL cholesterol between and within individuals, is explained by established predictors","volume":"184","author":"Jeffs","year":"2006","journal-title":"Atherosclerosis"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta191000\/hta191000.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta191000\/hta191000.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:36:02Z","timestamp":1692113762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta191000\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":284,"journal-issue":{"issue":"100","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["10.3310\/hta191000"],"URL":"https:\/\/doi.org\/10.3310\/hta191000","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}